61032-42-6

Basic information

• Product Name: Methyl 2-amino-4-benzyloxy-5-methoxybenzoate
• Synonyms: Methyl 2-amino-4-benzyloxy-5-methoxybenzoate;2-Amino-4-benzyloxy-5-methoxybenzoic acid methyl ester
• CAS NO: 61032-42-6
• Molecular Formula: C₁₆H₁₇NO₄
• Molecular Weight: 287.31048
• Mol File: 61032-42-6.mol
• Article Data: 24

Chemical Properties

• Melting Point: 131-132℃
• Boiling Point: 450.038 °C at 760 mmHg
• Flash Point: 199.203 °C
• Appearance: /
• Density: 1.205
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.67±0.10(Predicted)
• CAS DataBase Reference: Methyl 2-amino-4-benzyloxy-5-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-amino-4-benzyloxy-5-methoxybenzoate(61032-42-6)
• EPA Substance Registry System: Methyl 2-amino-4-benzyloxy-5-methoxybenzoate(61032-42-6)

Safety Data

• Hazardous Substances Data: 61032-42-6(Hazardous Substances Data)

Usage

Description

Methyl 2-amino-4-benzyloxy-5-methoxybenzoate is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. It is characterized by the presence of an amino group, a benzyloxy group, and a methoxy group attached to a benzene ring, which contribute to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
Methyl 2-amino-4-benzyloxy-5-methoxybenzoate is used as a reactant/reagent for the preparation of cyanoquinolines, which are known as protein tyrosine kinase inhibitors. These inhibitors play a crucial role in the development of drugs targeting various diseases, including cancer and autoimmune disorders, by modulating the activity of specific enzymes involved in cellular signaling pathways.

Upstream product

• 111627-40-8 methyl 4-(3-chloropropoxy)-3-methoxybenzoate 
• 100-44-7 benzyl chloride 
• 27883-60-9 4-hydroxy-5-methoxy-2-nitrobenzoic acid methyl ester 
• 100-39-0 benzyl bromide 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 1486-53-9 4-(benzyloxy)-3-methoxybenzoic acid 
• 61032-41-5 methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 121-33-5 vanillin 

Downstream Products

• 155666-33-4 2-amino-4-benzyloxy-5-methoxybenzoic acid 
• 1236153-14-2 4-[(3-fluorophenyl)amino]-6-methoxy-7-(prop-2-ynyloxy)quinazoline 
• 1236153-16-4 4-(3-fluoroanilino)-6-methoxy-7-benzyloxyquinazoline 
• 1236153-17-5 C₁₅H₁₂FN₃O₂ 
• 1236153-18-6 4-[(3-fluorophenyl)amino]-6-methoxy-7-(3,6,9,12-tetraoxapentadecan-14-ynyloxy)quinazoline 
• 162364-72-9 7-benzyloxy-4-chloro-6-methoxyquinazoline 
• 179688-01-8 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one 
• 1188908-02-2 1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)urea 
• 1188908-03-3 C₂₂H₁₉N₃O₃ 
• 1188908-04-4 4-(3-aminophenoxy)-6-methoxyquinazolin-7-ol 
• 179688-01-8 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 162012-72-8 7-hydroxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 179688-02-9 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 179688-03-0 4-chloro-6-methoxyquinazolin-7-yl acetate 

Relevant articles and documents

Method for preparing vanonitinib and analogue intermediate thereof through electro-reduction

The invention relates to an electroreduction preparation method of 2-amino-5-methoxybenzoic acid derivatives represented by a formula I shown in the specification. A preparation reaction is shown in the specification, wherein n is selected from 1, 2 or 3;

Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2

EGFR and VEGFR-2 are involved in pathological disorders and the progression of different kinds of tumors, the combined blockade of EGFR and VEGFR signaling pathways appears to be an attractive approach to cancer therapy. In this work, a series of 4-anilinoquinazoline derivatives containing substituted diaryl urea or glycine methyl ester moiety were designed and identified as EGFR and VEGFR-2 dual inhibitors. Compounds 19i, 19j and 19l exhibited the most potent inhibitory activities against EGFR (IC50?=?1?nM, 78?nM and 51?nM, respectively) and VEGFR-2 (IC50?=?79?nM, 14?nM and 14?nM, respectively), they showed good antiproliferative activities as well. Molecular docking established the interaction of 19i with the DFG-out conformation of VEGFR-2, suggesting that they might be type II kinase inhibitors.

Identification and Structure–Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1

The methyllysine reader protein Spindlin1 has been implicated in the tumorigenesis of several types of cancer and may be an attractive novel therapeutic target. Small-molecule inhibitors of Spindlin1 should be valuable as chemical probes as well as potential new therapeutics. We applied an iterative virtual screening campaign, encompassing structure- and ligand-based approaches, to identify potential Spindlin1 inhibitors from databases of commercially available compounds. Our in silico studies coupled with in vitro testing were successful in identifying novel Spindlin1 inhibitors. Several 4-aminoquinazoline and quinazolinethione derivatives were among the active hit compounds, which indicated that these scaffolds represent promising lead structures for the development of Spindlin1 inhibitors. Subsequent lead optimization studies were hence carried out, and numerous derivatives of both lead scaffolds were synthesized. This resulted in the discovery of novel inhibitors of Spindlin1 and helped explore the structure–activity relationships of these inhibitor series.